Patent US5736137A successfully refreshed from Google Patents.
US5736137A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
Assignee: Biogen Inc
•
Filing: 1993-11-03
•
Granted: 1998-04-07
•
Expires: 2013-11-03
Abstract
Abstract Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of immunologically active mouse/human chimeric anti-CD20 antibodies, radiolabeled anti-CD20 antibodies, and cooperative strategies comprising the use of chimeric anti-CD20 antibodies and radiolabeled anti-CD20 antibodies.
Inventors
- 👤 Darrell R. Anderson
- 👤 Nabil Hanna
- 👤 John E. Leonard
- 👤 Roland A. Newman
- 👤 Mitchell E. Reff
- 👤 William H. Rastetter
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-09 14:18
CPC Classifications
C; C07; C07K; C07K16/00; C07K16/18; C07K16/28; C07K16/2887; A; A61; A61K; A61K47/00; A61K47/50; A61K47/51; A61K47/68; A61K47/6835; A61K47/6849; A61P; A61P35/00; A61P35/02; A61K39/00; A61K2039/505; A61K38/00; C07K2317/00; C07K2317/20; C07K2317/24; C07K2317/70; C07K2317/73; C07K2317/732; C07K2319/00; Y; Y10; Y10S; Y10S424/00; Y10S424/80; Y10S424/801; Y10S530/00; Y10S530/867
Claims Analysis
Total Claims: 7
Claim 1
Independent Claim
18 words
Immunologically active, chimeric anti-CD20 antibody produced from a transfectoma comprising anti-CD20 in TCAE 8, ATCC deposit number 69119.
Claim 2
Dependent Claim
18 words
Immunologically active, chimeric anti-CD20 antibody produced from a transfectoma comprising anti-CD20 in TCAE 8, ATCC deposit number 69119.
Claim 3
Dependent Claim
15 words
A pharmaceutical composition comprising the anti-CD20 antibody of claim 1 in a pharmaceutically acceptable carrier.
Claim 4
Dependent Claim
29 words
The composition of claim 2, which contains a pharmaceutically acceptable carrier or excipient selected from the group consisting of sterile saline, sterile buffered water, propylene glycol and mixtures thereof.
Claim 5
Dependent Claim
27 words
The composition of claim 2, which contains a pharmaceutically acceptable dosage of the antibody which ranges from about 0.001 to about 30 mg/kg of human body weight.
Claim 6
Dependent Claim
26 words
The composition of claim 4, which contains a pharmaceutically acceptable dosage of the antibody which ranges from about 0.01 to about 25 mg/kg human body weight.
Claim 7
Dependent Claim
26 words
The composition of claim 5, which contains a pharmaceutically acceptable dosage of the antibody which ranges from about 0.4 to about 20.0 mg/kg human body weight.
References Cited (Backward Citations)
EP0125023B1
Cited
EP0173494A2
Cited
EP0274394A2
Cited
WO1988004936A1
Cited
US5500362A
Cited
EP0682040A1
Cited
EP0451216B1
Cited
WO1992007466A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2001-04-06 | 2001-10-06 | 2002-04-07 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2005-04-06 | 2005-10-06 | 2006-04-07 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2009-04-06 | 2009-10-06 | 2010-04-07 | $7700.00 | Window Closed / Lapsed |